GSK3B and pancreatic neoplasm: As in the case of chemotherapeutics used for pancreatic cancer treatment, introduction of WT-GSK-3β into MIA-PaCa-2 cells resulted in an increase of the IC50 values, i.e., decrease of sensitivity, of the cells to all the tested compounds.